APA (7th ed.) Citation

TF, C., ZJ, L., HS, Z., & R, Y. (2025). Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer. Drug Design, Development and Therapy, ume 19(Issue 1), 4991-5005.

Chicago Style (17th ed.) Citation

TF, Chen, Li ZJ, Zhao HS, and Yang R. "Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer." Drug Design, Development and Therapy ume 19, no. Issue 1 (2025): 4991-5005.

MLA (9th ed.) Citation

TF, Chen, et al. "Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer." Drug Design, Development and Therapy, vol. ume 19, no. Issue 1, 2025, pp. 4991-5005.